2005•Zhongguo quanke yixueRequires access

A Clinical Effective Analysis of Venlafaxine in Treatment of Somatoform Disorders

HU Wei-ming

Open publisher page 1 citations

Abstract

Objective To observe the clinical efficacy and side effects of venlafaxine in the treatment of somatoform disorders.Methods 68 patients with somatoform disorders were randomly assigned to receive venlafaxine or amitriptyline for six weeks,the patients were measured with clinical global impression scale (CGI-SI) and somatization in symptom checklist 90 (SCL-90) before treatment and at the 1st,2nd,4th,6th weekend after treatment,the treatment emergent symptoms scale(TESS) was used to assess the side effects at the 1st,2nd,6th weekend after treatment.Results There was no effective difference in the two groups( P 0.05),but there was difference in the effective time of drugs of the two groups( P 0.01).The score of SCL-90 somatoform gene was similar between the two groups before and after the treatment except at the end of 1-week treatment,there was no obvious significance( P 0.01).Conclusion Venlafaxine is an effective and safe drug to treat the patients with somatoform disorders.

About this research paper

What this paper is about

Objective To observe the clinical efficacy and side effects of venlafaxine in the treatment of somatoform disorders.Methods 68 patients with somatoform disorders were randomly assigned to receive venlafaxine or amitriptyline for six weeks,the patients were measured with clinical global impression scale (CGI-SI) and somatization in symptom checklist 90 (SCL-90) before treatment and at the 1st,2nd,4th,6th weekend after treatment,the treatment emergent symptoms scale(TESS) was used to assess the side effects at the 1st,2nd,6th weekend after treatment.Results There was no effective difference in the two groups( P 0.05),but there was difference in the effective time of drugs of the two groups( P 0.01).The score of SCL-90 somatoform gene was similar between the two groups before and after the treatment except at the end of 1-week treatment,there was no obvious significance( P 0.01).Conclusion Venlafaxine is an effective and safe drug to treat the patients with somatoform disorders.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the clinical efficacy and side effects of venlafaxine in the treatment of somatoform disorders.Methods 68 patients with somatoform disorders were randomly assigned to receive venlafaxine or amitriptyline for six weeks,the patients were measured with clinical global impression scale (CGI-SI) and somatization in symptom checklist 90 (SCL-90) before treatment and at the 1st,2nd,4th,6th weekend after treatment,the treatment emergent symptoms scale(TESS) was used to assess the side effects at the 1st,2nd,6th weekend after treatment.Results There was no effective difference in the two groups( P 0.05),but there was difference in the effective time of drugs of the two groups( P 0.01).The score of SCL-90 somatoform gene was similar between the two groups before and after the treatment except at the end of 1-week treatment,there was no obvious significance( P 0.01).Conclusion Venlafaxine is an effective and safe drug to treat the patients with somatoform disorders.

Key concepts: Venlafaxine, Medicine, Clinical Global Impression, Somatization, Somatization disorder, Amitriptyline, Internal medicine, Psychiatry

Related papers

Back to paper searchBrowse research topicsOriginal source
A Clinical Effective Analysis of Venlafaxine in Treatment of Somatoform Disorders — Research Paper | ScholarLens